SCHEDULE: ARCH Venture Funds Maintain Significant Stake in Neumora

ARCH Venture Funds and affiliated entities continue to hold a substantial beneficial ownership stake in Neumora Therapeutics, Inc., as detailed in a recent Schedule 13D amendment.

Summary

• ARCH Venture Fund VII, L.P., ARCH Venture Fund VIII Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., and ARCH Venture Fund XII, L.P., along with their general partners and managing directors, collectively beneficially own 33,847,838 shares of Neumora Therapeutics, Inc. common stock.
• This collective ownership represents 18.6% of the outstanding common stock of Neumora Therapeutics, Inc.
• Kristina Burow beneficially owns 33,965,419 shares, including 27,617 shares of common stock, 67,283 vested options, 2,581 options vesting within 60 days, and 20,100 fully vested restricted stock units, representing 18.7% of the class.
• Steven Gillis beneficially owns 31,526,272 shares, representing 17.3% of the class.
• Clinton Bybee beneficially owns 3,708,794 shares, representing 2.0% of the class.
• The percentages are calculated based on 182,040,945 shares of Common Stock outstanding, as reported by Neumora Therapeutics, Inc. in its Annual Report on Form 10-K filed on March 30, 2026.
• No reporting person has effected any transactions in the Common Stock during the last 60 days.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as slightly positive, primarily because it confirms the continued significant and stable institutional backing from ARCH Venture Partners, a key investor in Neumora Therapeutics, Inc. The administrative nature of the amendment itself is neutral, but the sustained high ownership is a positive signal.

Positives

• Continued significant beneficial ownership by ARCH Venture Partners, a prominent venture capital firm, signals ongoing institutional confidence in Neumora Therapeutics, Inc.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that significant and sustained institutional ownership by specialized venture capital firms like ARCH Venture Partners is common in the biotechnology and pharmaceutical sectors, particularly for companies in development stages. This continued high stake suggests a long-term investment horizon and belief in the company's pipeline or strategic direction, aligning with typical venture capital investment strategies in life sciences.

Comparison to Industry Standards

• The beneficial ownership percentage of 18.6% by ARCH Venture Funds is substantial, indicating a lead investor role, which is typical for early-stage and growth-stage biotechnology companies backed by venture capital. For instance, Flagship Pioneering often holds similar or larger stakes in its portfolio companies like Moderna (MRNA) during their formative years, reflecting deep involvement and commitment.
• The inclusion of options and restricted stock units in individual beneficial ownership calculations (e.g., Kristina Burow) is standard practice for executives and directors, aligning with corporate governance best practices to reflect full economic interest.

Stakeholder Impact

• Shareholders: The continued significant ownership by ARCH Venture Partners may be viewed positively, signaling long-term commitment and confidence from a major institutional investor.

Key Dates

Keywords

Neumora Therapeutics, ARCH Venture Partners, Beneficial Ownership, Schedule 13D, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals